Life Sciences
Philips & DoD Ink $10M Deal for AI-Wearable Disease Detection
What You Should Know: The Department of Defense and Philips announced a $10M award to expand the readiness of our service members with the…
What You Should Know:
- The Department of Defense and Philips announced a $10M award to expand the readiness of our service members with the Rapid Assessment of Threat Exposure (RATE) AI wellness tool.
- The first group in this new cohort are theAir Force First Sergeants, who are responsible for overall squadron health and wellness.
- RATE is an AI algorithm, trained on clinical data from hospital-acquired infections to work with any off-the-shelf wearable to detect possible infection, acting like a “check engine light” for your body. By measuring 164 different biomarkers in the body, research shows the RATE algorithm can effectively detect infection as early as six days prior to diagnostic testing, with an average of 2.3 days.
- The plan is for RATE to be device agnostic, but the current deployment of wearables will include Garmin watches and Oura rings. As the Philips-DIU team continues to prove out the new dataflow, the effort aims to add three additional popular wearable devices. The 11,000 former RATE users will also be able to re-affiliate with the projects if they still have the hardware.
biomarkers
wellness
diagnostic
health
hospital
device
hardware
devices
ai
Continue Reading
Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner
The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….